Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1)
NASH-TAG
NASH
Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH
NASH and Fibrosis Conference
Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640
EASL International Liver Congress
The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH
EASL International Liver Congress
